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ABSTRACT 
 
Diabetes mellitus (hereinafter referred to as diabetes) is a serious health 
concern affecting the daily lives of many Americans in both clinical and financial 
aspects. Diabetes affects approximately 26 million people of all ages in the United 
States, and the total estimated medical costs of diagnosed diabetes in the U.S. in 
2012 exceeded $200 billion. To obtain better health outcomes, prevent 
complications, and reduce unnecessary costs, some health insurance plans 
encourage patients to enroll in diabetes management programs that monitor 
patient's health status more closely and assist in the adoption of healthy behaviors 
and habits. The aims of this study are to compare medication adherence rates and 
total healthcare cost among patients participating in a Diabetes Care Management 
Incentive Program offered by a commercial health insurer with usual care. 
This study was performed using a retrospective cohort study design; 
subjects were insurance plan members with diabetes using metformin-containing 
medications. Logistic regression analyses were performed to measure the degree of 
association between intervention status (i.e. participation in the diabetes incentive 
program) and adherence rates. The adjusted odds ratio with 95% confidence 
intervals were reported as the measure of effect. For the total healthcare cost 
analysis, the Mann-Whitney U test was utilized to evaluate differences between the 
median intervention and non-intervention cost values. 
Odds ratios for rates of achieving medication possession ratio (MPR) of 
0.80 or greater among the intervention group as compared with the non-
intervention groups were 0.966 (95% CI: 0.739 - 1.264) in the bivariate logistic 
regression model, 0.995 (95% CI: 0.755 -1.312) in the full logistic regression 
  
model, and 1.008 (95% CI: 0.765 - 1.328) in the fitted logistic regression model. 
Additionally, the mean annual total healthcare cost was $8,827.01 ($735.58 per 
month) in the intervention group and $10,096.53 ($841.38 per month) in the non-
intervention group), yet the difference was not statistically significant (p = 0.2327).  
Study results indicate that the medication adherence rates among patients 
using metformin-containing medications were similar between members who were 
enrolled in the diabetes management program and members who were not enrolled 
in the program. However, members participating in the program incurred 
approximately $2,200 less in annual total healthcare cost.
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CHAPTER 1 
 
BACKGROUND 
 
Diabetes mellitus (hereinafter referred to as diabetes) is a serious health 
concern affecting the daily lives of many Americans. Diabetes affects 
approximately 25.8 million people of all ages in the United States, and the affected 
number is projected to increase due to an increase in the number of older 
Americans and increase in the prevalence of obesity due to westernized diets and 
sedentary lifestyles.
1-2
 
Diabetes is an acute and chronic disease caused by high blood glucose 
level requiring continuous monitoring and management. There are two major types 
of diabetes: Type 1 and Type 2. Type 1 diabetes, which accounts for 
approximately 5 to 10% of all diabetes cases, is caused by absolute insulin 
deficiency and is treated by exogenous insulin.
3
 Type 2 diabetes, the most common 
type of diabetes, accounting for approximately 90 to 95% of all cases, is 
characterized by insulin sensitivity and insulin secretion defects.
4 
People with type 
2 diabetes have various treatment options including oral hypoglycemic agents and 
insulin. Among patients with type 2 diabetes, approximately 24% do not recognize 
they have diabetes.
4
 
The total estimated medical costs of diagnosed diabetes in the U.S. in 2012 
was $245 billion, a 40% increase from $174 billion in 2007, and the cost will 
continue to increase due to an increasing number of patients having diabetes.
5
This 
expenditure includes both direct medical costs such as hospital inpatient care, 
prescription medications, physician office visits, and residential/nursing facility 
 2 
 
stays, and indirect medical costs such as reduced productivity and inability to 
work.
5
 
 To obtain better health outcomes, prevent complications, and reduce 
unnecessary costs, some health insurance plans encourage patients to enroll in 
diabetes management programs. Typical components of diabetes management 
programs, include periodic physical examinations, appointment reminders by 
health care personnel, patient education to enhance self-management skills and 
encourage healthful behaviors such as daily exercises and eating more fresh fruits 
and vegetables, and laboratory examinations including cholesterol levels, liver 
function tests, and blood glucose levels. 
Research evaluating the effectiveness of diabetes management programs 
have assessed clinical outcomes such as decrease in hemoglobin A1c level, 
cardiovascular risks, and foot infection risks to determine effectiveness.
6-7
For 
example, the Asheville Project, a disease management program, started in 1996 by 
the city of Asheville, North Carolina.
8
The program enrolled patients with asthma, 
hypertension, hypercholesterolemia and diabetes and provided educational and 
personal disease management services for employees of the city of Asheville.
8
 
Participants with diabetes experienced improved hemoglobin A1C levels, lower 
total health care costs, and fewer sick days.
8
A long term follow-up study 
determined that approximately 50% of participants experienced decreases in mean 
hemoglobin A1c and lipid level at each follow-ups.
9
Another study evaluated the 
association between a health maintenance organization (HMO) sponsored diabetes 
management program and hemoglobin A1c level and determined that individuals 
participating in the diabetes management program improved short-term glycemic 
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control significantly.
10
 According to the study, mean hemoglobin A1c of patients 
decreased from 8.51to 7.41 after 3 months of follow-up.
10
 
However, there is a lack of study of the cost effectiveness of diabetes 
management programs, due to the difficulty and complexity in describing 
economic outcomes.
11
 It is often difficult to gather all of the diabetes-related direct 
and indirect costs, and as a result, less is known about the disease management 
programs' impact on medical expenditure for patients with diabetes.
11-
12
Nonetheless,results of one study suggested that intensified diabetes care 
management activities increased diabetes medication adherence by 4%, and 
another study determined that patients with diabetes that participated in the 
Asheville Project experienced a decrease in total mean direct medical costs of 
$1,200 to $1,872 per year compared to patients with diabetes who did not 
participate in the intervention. Additionally, the Asheville Project saved an 
employer group approximately $18,000 per year.
9,13
 However, not all diabetes 
management programs have a favorable impact on financial outcomes with 
incremental medical costs ranging from -$16,996 to $3,305 per patient per year.
14 
 This current study will assess the associations between enrollment in a 
diabetes management program provided by a commercial insurance plan and 
health expenditure and diabetes medication adherence rate. Diabetes management 
programs are known for assisting participants to achieve better diabetes medication 
adherence and ,eventually, better health outcomes, thus insurance plans can 
possibly reduce spending through better diabetes medication adherence and better 
health outcomes: less hospitalization, less diabetes complications and increase in 
work productivity.
15-16
Poor medication adherence causes approximately 125,000 
deaths due to increase in morbidity in hospitalizations.
17
 Furthermore, poor 
 4 
 
medication adherence costs the U.S. health care system up to $289 billion 
annually.
17
In addition, cost burdens of diabetes are large with medication costs, 
frequent hospital visits, and possible hospitalizations, as noted above. 
The diabetes incentive program evaluated in our study aims to improve 
diabetes-related care and decrease medical expenses due to diabetes and diabetes-
related complications. The program provides participants' diabetes medications 
free of charge if they agree to participate in an annual physical examination, 
complete a hemoglobin A1c blood test at least twice a year, have an annual low 
density lipoprotein cholesterol test, participate in case coordination led by case 
managers, and personalized support and educational sessions provided by a 
registered nurses and dieticians.  
This study will help in fulfilling pharmacoeconomic-research demands 
about diabetes management programs and contribute to the development of more 
economically efficient diabetes management programs. The study's hypothesis is 
that the members enrolled in the diabetes management program will achieve higher 
medication adherence rate than those who are not enrolled in the diabetes 
management program. A secondary hypothesis is that the members enrolled in the 
diabetes management program will experience reduced total healthcare 
expenditure compared to the members nor enrolled in the diabetes management 
program.  
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CHAPTER 2 
 
METHOD 
 
This study was a retrospective cohort study, assessing the association 
between a diabetes management program and its effects on participants' medication 
adherence and medical costs. The data were provided by a commercial health 
insurer, and included members' medical diagnoses, basic demographics, medical 
and pharmacy spending information, and health care procedures. The dataset 
includes members who enrolled in the Diabetes Incentive Program (intervention) 
and who did not enroll (non-intervention) between January 1st of 2008 and May 
31st of 2010. Through the participation of the Diabetes Incentive Program, 
members were able to obtain the following health management services: (a) 
participate in care coordination with a case manager, (b) have an annual physical 
examination, (c) have a hemoglobin A1c blood test at least twice annually, (d) 
have a low density lipoprotein cholesterol (LDL-C) test at least once annually, and 
(e) attend dietary, lifestyle, and diabetes management educational sessions led by 
registered nurses and dieticians If members participated in all of these services, 
they received a substantial to full price discounts on their hypoglycemic 
prescriptions.  
 In order to be included in the study population, patients had to be aged 18 
years or above and have at least 1 ICD-9-CM (The International Classification of 
Diseases, Ninth Revision, Clinical Modification) for diabetes, and at least 1 claim 
for an anti-diabetic medication during the last 12-month period of continuous 
enrollment (365 days). In this study, only metformin and metformin-containing 
combination medications were considered as metformin is the first line oral 
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hypoglycemic agent.
18
 In addition, patients with diabetes generally utilize 
metformin continuously, whereas other diabetes medications such as sulfonylurea 
and dipeptidyl peptidase-4 (DPP-4) inhibitors are used as add-on therapies. All 
possible metformin-containing combination medications on the market were 
included in this study (see Appendix A). To assist in identifying all metformin-
containing medications, drug information databases Clinical Pharmarmacology® 
and Micromedex® were used.
 
 Patient gender, comorbidities, insulin usage, the total number of 
medications used (diabetes and non-diabetes), and age group were defined as 
categorical variables. Cardiovascular diseases, pulmonary diseases, and mental 
health disorders were the examined comorbidities, and were determined based on 
published ICD 9 code sets (see Appendix B,C,D,E,F,G). The total number of 
dispensed medications represented the number of different prescription 
medications dispensed to these patients for 12 months. Quartiles of frequency 
distribution were used to categorize the total number of dispensed medications: 
group 1 (1-7 total medications), group 2 (8-13 total medications), group 3 (14-17 
total medications) and group 4 (18 and more total medications). Age was described 
as a continuous variable; and then categorized according to groupings that 
generally reflected older (age of 65 and above), middle aged (age of 50 to 64), and 
young adult patients (age of 18 to 49). 
 
Statistical analysis (Medication adherence) 
 The first analysis assessed the relationship between enrollment in the 
Diabetes Incentive Program and the diabetes medication adherence rate. To 
measure the medication adherence rate, the study utilized MPR (Medication 
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Possession Ratio), calculated as the sum of the days supply for all relevant 
medication dispensing during the measurement period, divided by the number of 
days elapsed during the period.
19-21
This study evaluated MPR based on 12-month 
elapsed period of enrollment in the diabetes management program. If a patient had 
an MPR of equal to or higher than 0.80 (80%), the patient was classified as being 
adherent to the diabetes medication. For these analyses, we focused on dispensings 
of metformin-containing medications, regardless of different strengths, dosage 
forms, and releasing forms. 
Chi-square tests were performed to determine if there were differences in 
the percentage of patients classified as adherent and those enrolled and not enrolled 
in the Diabetes Incentive program. Multivariate logistic regression analyses were 
performed to determine the association between the enrollment in the Diabetes 
Incentive Program and the MPR (dependent variable), controlling for other 
independent variables including patient age group, gender, comorbidities, insulin 
usage, and the total number of medications dispensed. Independent variables were 
assessed for co-linearity, and the Hosmer-Lemeshow goodness of fit test was 
performed to assess the calibration of the final model. The adjusted odds ratio with 
95% confidence intervals were reported as the measure of effect. 
 
Statistical analysis (Healthcare cost) 
 The second analysis assessed differences in health care cost among 
patients with diagnosed diabetes participating in the Diabetes Incentive Program 
and those receiving usual care. We determined health expenditures for the range of 
utilized health services, including hospitalization costs and diabetes medication 
costs of participants who were enrolled in the Diabetes Incentive Program and for 
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those who were not enrolled in the Diabetes Incentive Program. Costs were 
defined as the amount paid by the health insurance plan, which does not include 
copayments made by patients. Costs included both diabetes-related and non-
diabetes related physician visits, hospitalizations, laboratory tests, and prescription 
drug costs. Total healthcare expenditures during the 12 month timeframe was 
compared between intervention and non-intervention groups.  
The distribution of costs was analyzed prior to determining the appropriate 
statistical test for evaluating group differences in healthcare spending. Mean costs 
by group were reported, and where data were skewed, a log transformation was 
performed. The student's t-test was used to assess mean differences in cost, and 
given the skewed nature of the data, median-based tests were also performed to 
assess the statistical significance of these cost differences.  
 These costs analyses included the same independent variables from the 
adherence analysis: age, gender, comorbidities, insulin usage, and total number of 
medications dispensed. To evaluate the statistical significance of differences in 
these baseline characteristics and health expenditure, the students t-test was 
utilized. The Mann-Whitney U test was also utilized to evaluate differences 
between the median intervention and non-intervention cost values. 
 Data analysis was performed using SAS (version 9.3). 
 
  
 9 
 
CHAPTER 3 
 
RESULTS 
 
A total of 284 intervention members and 5,528 non-intervention members 
met all the cohort selection criteria (see Figure A). The intervention group had a 
mean age of 54.06 years (SD=9.50) and the non-intervention group had a mean age 
of 54.59 years (SD=8.59) (see Table 1).About one-quarter in the intervention 
group (26.06%, n=74) and the non-intervention group (25.92%, n=1,433) were 
between 18-49 years of age. The frequency of the population aged50-64 years was 
61.97% in the intervention group and 64.36%, while the frequency of population 
who is 65 years and above was 11.97% in the intervention group and 9.71% in the 
non-intervention group. Percent differences across age groups were not statistically 
significant (p=0.4396). 
The frequency of males was 61.27% in the intervention group and 61.09% 
in the non-intervention group, and the frequency of females was 38.73% in the 
intervention group and 38.91% in the non-intervention group. Although it was not 
a statistically significant difference, the frequency of insulin use was 39.79% in the 
intervention group and 35.42% in the non-intervention group (p=0.952). 
Differences in the prevalence of the comorbidities of respiratory disease and 
cardiovascular disease were statistically significant between the two groups 
(p=0.0409 Respiratory disease, p=0.0026 Cardiovascular disease); 7.04% of the 
intervention group and 10.89% of the non-intervention group had a respiratory 
disease, while 7.04% of the intervention group and 13.17% of the non-intervention 
group had a documentation of cardiovascular disease, respectively. Additionally, 
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15.49% of the intervention group and 14.35% of the non-intervention group had a 
mental health disorder, although this difference was not statistically significant 
(p=0.5920).The frequency of thoseusing1 to 7 total medications was 25.00% in the 
intervention group and 20.98% in the non-intervention group, and the frequency of 
those using 8 to 13 total medications was 29.58% in the intervention group and 
31.35% in the non-intervention group. The frequency of those using 14 to 17 total 
medications was 16.90% in the intervention group and 16.75% in the non-
intervention group, and the frequency of those using more than 18 total 
medications was 28.52% in the intervention group and 30.92% in the non-
intervention group. The frequency based on the number of total medications was 
not statistically significant, and both intervention and non-intervention patients 
appeared to utilize a similar number of medications during the measurement period. 
  
Results (Medication adherence) 
Result assessing medication adherence revealed that 72.89% of the 
intervention group and 73.55% of the non-intervention group achieved MPR of 
0.80 or greater, although this difference was not statistically significant (p=0.8042). 
Mean ages of the subgroups who achieved MPR greater than or equal to 0.80 and 
who did not achieve MPR of 0.80 or higher were 55.24 and 52.64, respectively 
(p=<0.0001, SD=8.34 and 9.15) (see Table 2).Adherence rates increased with age: 
64.90% of the subgroup aged 18-49 years, 75.87% of the subgroup aged 50-64 
years old, and 80.91% of the subgroup aged 65 years old and above achieved MPR 
greater than or equal to 0.80 (p=<0.0001). Although this finding was not 
statistically significant (p=0.2646), 74.04% of male and 72.71% of female 
achieved MPR greater than or equal to 0.80. Patients utilizing higher numbers of 
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medications were more frequently classified as adherent to the diabetes 
medications: 60.60% of the subgroup using 1 to 7 total medications, 70.17% of the 
subgroup using 8 to 13 total medications, 77.31% of the subgroup using 14 to 17 
total medications, and 83.74% of the subgroup using more than 18 total 
medications achieved MPR greater than or equal to 0.80 (p=<0.0001).Among 
patients with documented mental health disorders, 74.17% of the subgroup without 
mental health disorders and 69.38% of subgroup with mental health disorders 
achieved MPR greater than or equal to 0.80 (p=0.0037). For cardiovascular disease, 
72.87% of the subgroup without cardiovascular disease and 77.64% of the 
subgroup with cardiovascular disease achieved MPR greater than or equal to 0.80 
(p=0.0058).  
 Being enrolled in the intervention was not associated with higher 
medication adherence rate in the bivariate logistic regression analysis(see Table 3). 
Both the intervention group and the non-intervention group had a similar 
likelihood of achieving MPR of 0.80 (OR= 0.966; 95% CI: 0.739 - 1.264). 
Increasing age was associated with increased likelihood of achieving MPR of 0.80 
or greater. The subgroup aged 50 to 64 years was 39% more likely to have been 
adherent (OR 1.393; 95% CI: 1.236 - 1.570), while the subgroup aged65 years and 
above was 59% more likely to have been adherent (OR 1.590; 95% CI: 1.279 - 
1.975). Female members had similar likelihood of achieving MPR of 0.80 or 
greater as the male members, with an odds ratio of 0.934 (95% CI: 0.830 - 1.053). 
If members were taking more medications, they were more likely to achieve MPR 
of 0.80 or greater. The subgroup taking 8 to 13 total medications was 22% less 
likely to have been adherent (OR 0.782; 95% CI: 0.691 - 0.885). The subgroup 
taking 14 to 17 total medications was 27% more likely to have been adherent (OR 
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1.276; 95% CI: 1.084 - 1.501) while the subgroup taking 18 or more medications 
was 131% more likely to have been adherent (OR 2.317; 95% CI: 2.010 - 2.672). 
 Based on the saturated logistic regression model, the impact of 
intervention group status was also not significantly associated with medication 
adherence (see Table 4). The intervention group had similar likelihood of 
achieving MPR of 0.80 or greater as the non-intervention group, with an adjusted 
odds ratio of 0.995 (95% CI: 0.755 - 1.312).Similar to results from the bivariate 
logistic regression analysis, if members were older, they were more likely to 
achieve MPR of 0.80 or greater. 
The patient subgroup aged 50 to 64 years was 46% more likely to have 
been adherent (OR 1.467; 95% CI: 1.283 - 1.679), while the subgroup aged 65 
years and above was 89% more likely to have been adherent (OR 1.897; 95% CI: 
1.488 - 2.418), (p=<0.0001). Female members had similar likelihood of achieving 
MPR of 0.80 or greater as the male members, with an adjusted odds ratio of 0.909 
(95% CI: 0.802 - 1.030). Also, similar to results from the bivariate logistic 
regression analysis, if members were taking more medications, they were more 
likely to achieve MPR of 0.80 or greater. The subgroup taking 8 to 13 total 
medications was 49% more likely to be adherent (OR1.493; 95% CI:1.279 - 
1.744).The subgroup taking 14 to 17 total medications was 119% more likely to 
have been adherent (OR 2.194; 95% CI: 1.810 - 2.659), while the subgroup taking 
18 or more medications was 248% more likely to have been adherent (OR 3.480; 
95% CI:2.905 - 4.170),(p=<0.0001). 
 In the fitted multiple logistic regression model, the impact of intervention 
group status was not statistically significant (see Table 5). The intervention group 
had similar likelihood of achieving MPR of 0.80 or greater as the non-intervention 
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group, with an adjusted odds ratio of 1.008 (95% CI: 0.765 - 1.328).Older 
members were more likely to achieve MPR of 0.80 or greater. Those aged 50 to 64 
years were 45% more likely to have been adherent (OR 1.458;95% CI: 1.276 - 
1.667), and individuals aged 65 years and above were 86% more likely to be 
adherent (OR 1.861; 95% CI: 1.464 - 2.365), (p=<0.0001). If members were taking 
more medications, they were more likely to achieve MPR of 0.80 or greater. The 
subgroup taking 8 to 13 total medications was 49% more likely to have been 
adherent (OR 1.492; 95% CI: 1.279 - 1.742). The subgroup taking 14 to 17 total 
medications was more than twice as likely to have been adherent (OR 2.161; 95% 
CI: 1.784 - 2.618), while the subgroup taking 18 or more total medications was 
more than 3 times as likely to have been adherent (OR 3.354; 95% CI: 2.809 - 
4.005), (p=<0.0001). Good model calibration was shown by the Hosmer-
Lemeshow goodness of fit test with a p-value of 0.3768, implying good matching 
between expected and observed event rates in population's subgroup. 
  
Results (Healthcare cost) 
Although it was not statistically significant (p=0.2327), The mean annual 
per patient total healthcare cost, including both pharmacy-related cost and medical 
cost, was $8,827.01 ($735.58 per month) in the intervention group and $10,096.53 
($841.38 per month) in the non-intervention group (see Table 6). The mean annual 
per patient pharmacy-related cost was $2,904.92 ($242.08 per month) in the 
intervention group and $2,655.21 ($221.27 per month) in the non-intervention 
group (p=0.2065), and the mean medical cost was $5,922.08 ($493.51) in the 
intervention group and $7,438.93 ($619.91 per month) in the non-intervention 
group (p=0.1363).  
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The mean total healthcare costs of male and female patients in the 
intervention group were $7,761.1 and $10,513.0 respectively, and the mean total 
healthcare costs of males and females in the non-intervention group were $9,785.9 
and $10,583.1, respectively(see Table 7). Analysis of age groups revealed a mean 
total healthcare cost of intervention and non-intervention population aged 18 to 49 
years to be $7,015.2 and $8,244.1, respectively. For those who were 50 to 64 years 
old, intervention group had the mean total healthcare costs of $9,117.0, and non-
intervention group had the mean total healthcare costs of $10,551.7. The mean 
total healthcare costs of intervention and non-intervention population who are 65 
years old and above were $11,269.4 and $12,028.0, respectively. All the mean total 
healthcare cost results based on different age groups were not statistically 
significant. For the total medication counts, the mean total healthcare costs of 
intervention and non-intervention members who are taking 1 to 7 total medications 
were $4,495.2 and $6,261.6, respectively. For those who are taking8 to 13 total 
medications, intervention group had the mean total healthcare costs of $6,836.4, 
and non-intervention group had the mean total healthcare costs of $7,661.0. The 
mean total healthcare costs of intervention and non-intervention members who are 
taking 14 to 17 total medications were $7,689.9 and $9,380.5, respectively. The 
mean total healthcare costs of intervention and non-intervention members who are 
taking 18 or more total medications were $15,362.3 and $15,548.9, respectively. 
 
  
 15 
 
CHAPTER 4 
 
DISCUSSION 
 
Diabetes mellitus is a serious obstacle for the United States health care 
system in both clinical and financial terms. Affecting approximately 8.3% of the 
U.S. population, it is the seventh leading cause of death, and is a major cause of 
cardiovascular diseases, the first leading cause of death in the U.S.
1,22
 
  
Discussion (Medication adherence) 
The first goal of this study was to determine whether the participation in a 
Diabetes Incentive Program provided by a commercial insurer affects the diabetes 
medication adherence rate. Contrary to the study hypothesis, members who were 
enrolled in the diabetes management program did not achieve higher MPR of 0.80 
or greater than members who were not enrolled in the diabetes management 
program. Odds ratios for rates of achieving MPR of 0.80 or greater among the 
intervention group as compared with the non-intervention groups were 0.966 (95% 
CI: 0.739 - 1.264) in the bivariate logistic regression model, 0.995 (95% CI: 0.755 
- 1.312) in the full logistic regression model, and 1.008 (95% CI: 0.765 - 1.328) in 
fitted logistic regression model. All three logistic regression analyses provided 
consistent results and demonstrated that the medication adherence rates with 
metformin-containing medications between members who were enrolled in the 
diabetes management program and members who were not enrolled in the diabetes 
management program were similar. 
 Medication adherence rates, however, were associated with age, total 
medication dispensings, and presence of mental health disorders. Older patients 
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were more likely to achieve MPR of 0.80 or greater than younger patients. The 
subgroup who were 50 to 64 years old had odds ratio of 1.458 (95% CI: 1.276 - 
1.667) in the fitted logistic regression model. The subgroup who were 65 years old 
and above had odds ratio of 1.861 (95% CI: 1.464 -2.365) in the fitted logistic 
regression model. Based on these consistent results, those older than 65 years old 
and above had approximately twice the likelihood of achieving MPR of 0.80 or 
greater than group that were 18 to 49 years old, indicating that older patients may 
manage their health conditions more diligently due to the possibility of having 
more comorbidities and health issues. 
Those using more medications were more likely to achieve MPR of 0.80 
or greater than those using less medications. All three logistic regression analyses 
provided consistent results of increasing likelihood of achieving MPR of 0.80 or 
greater if total medication counts increase. The subgroup using 18 or more 
medications had an odds ratio of 3.354 (95% CI: 2.809 - 4.005) in the fitted 
logistic regression model. Based on these results, subgroup using more 18 or more 
medications had approximately three times the likelihood of achieving MPR of 
0.80 or greater than population using 1 to 7 medications. These results reveal that 
members taking more medications were more adherent to their medications, which 
maybe indicating that members taking more medications regard the activity of 
medication intake more seriously due to their possibly less healthy status. 
Therefore, the diabetes management program should specifically target younger 
members taking less medications to improve their suboptimal medication 
adherence and enhance the program's performance. 
Among the three comorbidities evaluated, the subgroup having a diagnosis 
of a mental health disorder was less likely to achieve MPR of 0.80 or greater than 
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population without a mental health disorder. The population with mental health 
disorders had odds ratio of 0.703 (95% CI: 0.595 - 0.831) in the fitted logistic 
regression model. All three logistic regression analyses provided consistent results 
of decreasing likelihood of achieving MPR of 0.80 or greater if one has a 
documented mental health disorder. The presence of respiratory diseases or 
cardiovascular diseases did not affect the likelihood of achieving MPR of 0.80 or 
greater. The state of depression affects one's medication adherence due to 
decreased motivation and willingness. A meta analysis by Grenard et al (2011) 
found that depressed patients are 1.76 times more likely to be non-adherent to their 
medications compared to patients without depression.
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 Therefore, the diabetes 
management program should specifically target depressed patients to prevent 
patients' disengagement and improve program's performance. 
Other independent characteristics including gender were not associated 
with medication adherence. The subgroup that used insulin was less likely to 
achieve MPR of 0.80 or greater, although this association was not consistent across 
the three logistic regression models. In the fitted logistic regression model, the 
odds ratio for insulin use was 0.874 (95% CI: 0.769 - 0.993), (p=0.0379). This 
result is maybe due to the relationship between diabetes severity and insulin usage. 
If diabetes worsens, patients tend to switch to insulin therapy from oral diabetes 
medications including metformin. 
The results of this study indicate that an incentive-based diabetes 
management program did not yield increased rates of medication adherence among 
participants when compared with rates among members with diabetes not 
participating in the diabetes management program. Medication adherence rates 
were similar between the two groups in all three logistic regression statistical tests, 
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which indicates that the program likely did not yield clinical benefits as a 
consequence of more consistent medication taking. However, medication 
adherence rates were already fairly high among all patients included in this study, 
suggesting that the opportunity for improvement was limited. 
 
Discussion (Healthcare cost) 
The second aim of this study was to determine whether the participation of 
a Diabetes Incentive Program provided decreased health expenditures including 
both medical and pharmacy-related costs. Although the cost analyses performed 
did not reveal statistically significant differences in cost, members who were 
enrolled in the diabetes management program had lower total health expenditures 
than members who were not enrolled in the diabetes management program. The 
mean total healthcare cost, including both pharmacy-related cost and medical cost, 
was $8,827.01 ($735.58 per month) in the intervention group and $10,096.53 
($841.38 per month) in the non-intervention group. While patients in the diabetes 
management program incurred approximately $2,200 less in annual healthcare cost, 
cardiovascular and respiratory comorbidities were less prevalent among program 
participants. 
Total healthcare costs varied across several of the independent variables 
evaluated. As expected, older patients were more likely to have higher mean total 
healthcare cost than younger patients in both the intervention group and non-
intervention group. Female patients were more likely to have higher mean total 
healthcare cost than male patients in both the intervention group and non-
intervention group. Patients using insulin were more likely to have higher mean 
total healthcare cost than population not using any insulin in both intervention 
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group and non-intervention group, reflecting the progressed disease status among 
these patients. Patients using more medications were more likely to have higher 
mean total healthcare cost than population using less numbers of medications in 
both intervention group and non-intervention group. Analysis of the relationship 
between patient age and total medication dispensings suggested that these two 
continuous variables were not highly correlated (Spearman r = 0.179), suggesting 
that both increasing age and a greater number of medications used were 
independently associated with higher health care expenditure. 
As expected, patients with comorbidities (respiratory disease, mental 
health disorder, and cardiovascular disease) were more likely to have a higher 
mean total healthcare cost than population without comorbidities. When examining 
costs across comorbidity categories, the mean total healthcare costs of intervention 
and non-intervention population with respiratory diseases were $23,337.4 and 
$17,937.7, respectively; the mean total healthcare costs of intervention and non-
intervention population with cardiovascular diseases were $24,627.6 and $19,503.9, 
respectively. These results reveal that older members with more comorbidities and 
more medications prescribed incurred greater total healthcare costs. Based on this 
finding, diabetes management program should consider focusing on older members 
with comorbidities and use of a greater number of medications to reduce total 
healthcare costs through the programs components. 
 
Discussion (Limitations) 
There were several limitations in this study. First, intervention and non-
intervention groups were fundamentally different, and this difference prevented us 
to confirm that the diabetes management program solely contributed to 
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intervention group's lower total healthcare costs. In the intervention group, 
subgroups with respiratory diseases and cardiovascular diseases were 7.04% and 
7.04%, and in non-intervention group, subgroups with respiratory diseases and 
cardiovascular diseases were 10.89% and 13.17% (p=0.0409 and 0.0026). The 
intervention group was generally healthier than the non-intervention group.  
Additionally, there were no comparisons to medication adherence rates or 
cost in prior months. Without having access to previous data, the study was unable 
to determine if the intervention was progressively improving members' medication 
adherence and costs. It is possible that the intervention may have provided greater 
gains or losses in medication adherence and costs from the previous year than the 
non-intervention group, yet we were not able to evaluate the progressive impacts 
on the diabetes management program. Moreover, the study's 12-month evaluation 
period may have been too limited to measure the intervention's impact on 
medication adherence and total healthcare costs. 
Furthermore, the study was unable to determine the temporal relationships 
between examined variables due to the short time period for follow up. In this case, 
there is a possibility that some members could have been diagnosed with a 
cardiovascular disease on the last day of their enrollment periods of 12 months and 
would have been labeled as cardiovascular patients for the entire study period. This 
limitation could falsely increase cost burdens of participants with some 
comorbidities. An additional limitation is that the study only considered metformin 
and metformin-containing medications for adherence to diabetes medication. As  
metformin is usually the first line oral therapy agent for diabetes mellitus and non-
metformin medications are add-on therapies. Users of other oral diabetes 
medications such as sulfonylureas, DPP-4 inhibitors, or thiazolidinediones were 
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excluded in this study. The medication adherence rates of this study, therefore, 
could over-represent healthier populations, and overall oral diabetes medication 
adherence rates may be different from the result.   
Additionally, another study limitation is that the administrative data source 
only included information about paid claims and excluded any procedure or 
medication that were paid out-of-pocket. The study, also, assumed that members 
consumed the dispensed medications, but compliance to dispensed medications 
was not measured or assessed. There is a possibility that the study misclassified 
members that did not take medications that had been dispensed as adherent to their 
medications. Also, the data source did not include information about patient race, 
ethnicity, and socioeconomic factors, which may have been associated with both 
the independent variables studied and the outcomes of medication adherence, and 
total healthcare cost.  
There were cost outliers, affecting average medical, pharmacy, and total 
healthcare cost values. The highest cost for the non-intervention group was 
$345,862.33 and for the intervention group was $166,091.36. To evaluate the two 
groups not affected by the outliers, a median-based test was performed in the 
statistical analysis. Due to these outliers in the cost analysis, standard deviations 
became higher than mean values, and analysis results turned out to be statistically 
not significant.  
In addition, the lack of randomization may not avoid impacts from 
unidentified or unseen biases or confounders. Also, members deciding to enter the 
diabetes management program could have been more careful about their own 
health, and this may have possibly led to a selection bias. 
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CHAPTER 5 
 
CONCLUSION 
 
Results of this study found that a Diabetes Incentive Program did not 
improve participants' medication adherence rates. Although not statistically 
significant, participation was associated with reduced total healthcare costs. Older 
participants and those taking more medications were associated with greater 
adherence to diabetes medications but incurred greater total healthcare costs. 
Certain comorbidities such as mental health disorders also affected medication 
adherence and total healthcare costs adversely. Further studies about the Diabetes 
Incentive Program should be performed to evaluate changes in rates of medication 
adherence and total healthcare costs over time.  
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Table 1: Selected Characteristics of Patients Participating in the Diabetes 
Incentive Program and Patients in the Comparison Group (Intervention vs. 
Nonintervention) 
 
Variable Intervention (N=284) Non-intervention 
(N=5,528) 
P value 
 N % N %  
Mean [SD] age 54.056 [9.50] 54.585 [8.59] 0.3145 
Age group 
18-49 74 26.06 1,433 25.92 0.4396 
50-64 176 61.97 3,558 64.36 
65+ 34 11.97 537 9.71 
      
Gender 
   Male 174 61.27 3,377 61.09 0.952 
   Female 110 38.73 2,151 38.91 
      
Insulin 
No 171 60.21 3,570 64.58 0.1338 
Yes 113 39.79 1,958 35.42 
      
Total Medication Counts 
1-7 71 25.00 1,160 20.98 0.4178 
8-13 84 29.58 1,733 31.35 
14-17 48 16.90 926 16.75 
18+ 81 28.52 1,709 30.92 
      
Comorbidity (Respiratory diseases) 
   No 264 92.96 4,919 89.11 0.0409 
   Yes 20 7.04 601 10.89 
      
Comorbidity (Mental health disorders) 
   No 240 84.51 4,728 85.65 0.5920 
   Yes 44 15.49 792 14.35 
      
Comorbidity (Cardiovascular diseases) 
   No 264 92.96 4,793 86.83 0.0026 
   Yes 20 7.04 727 13.17 
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Table 2: Association Between Selected Characteristics of Study Patients and 
Diabetes Medication Adherence (Medication Possession Ratio (MPR)< 80 vs. 
MPR >= 80) 
 
Variable MPR < 80 MPR >= 80 P value 
 N % N %  
Mean [SD] age 52.64 [9.15] 55.24 [8.34] <0.0001 
    
Age group 
18-49 529 35.10 978 64.90 <0.0001 
50-64 901 24.13 2,833 75.87 
65+ 109 19.09 462 80.91 
      
Gender 
   Male 922 25.96 2,629 74.04 0.2646 
   Female 617 27.29 1,644 72.71 
      
Insulin 
No 991 26.49 2,750 73.51 0.9805 
Yes 548 26.46 1,523 73.54 
      
Total Medication Counts 
1-7 485 39.40 746 60.60 <0.0001 
8-13 542 29.83 1,275 70.17 
14-17 221 22.69 753 77.31 
18+ 291 16.26 1,499 83.74 
      
Comorbidity (Respiratory diseases) 
   No 1,368 26.39 3,815 73.61 0.5423 
   Yes 171 27.54 450 72.46 
      
Comorbidity (Mental health disorders) 
   No 1,283 25.83 3,685 74.17 0.0037 
   Yes 256 30.62 580 69.38 
      
Comorbidity (Cardiovascular diseases) 
   No 1,372 27.13 3,685 72.87 0.0058 
   Yes 167 22.36 580 77.64 
      
Intervention 
No 1,462 26.45 4,066 73.55 0.8042 
Yes 77 27.11 207 72.89 
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Table 3: Bivariate Logistic Regression Analysis Assessing the Likelihood of 
Diabetes Medication Adherence According to Selected Patient Characteristics 
 
 Beta OR 95 CI% 
low 
95% CI 
High 
P value 
      
Age group 
18-49 Ref     
50-64 0.3315 1.393 1.236 1.570 <0.0001 
65+ 0.4634 1.590 1.279 1.975 <0.0001 
      
Gender 
   Male Ref     
   Female -0.0678 0.934 0.830 1.053 0.2647 
      
Insulin 
No Ref     
   Yes 0.00152 1.002 0.887 1.131 0.9805 
      
Total Medication Counts 
1-7 Ref     
8-13 -0.2455 0.782 0.691 0.885 <0.0001 
14-17 0.2435 1.276 1.084 1.501 0.0034 
18+ 0.8405 2.317 2.010 2.672 <0.0001 
      
Comorbidity (Respiratory diseases)  
   No Ref     
   Yes -0.0580 0.944 0.783 1.137 0.5423 
      
Comorbidity (Mental health disorders)  
   No ref     
   Yes -0.2372 0.789 0.672 0.926 0.0037 
      
Comorbidity (Cardiovascular diseases) 
   No ref     
   Yes 0.2570 1.293 1.077 1.553 0.0059 
      
Intervention 
No ref     
Yes -0.0342 0.966 0.739 1.264 0.8028 
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Table 4: Saturated Model Logistic Regression Analysis: Likelihood of 
Adherence (Medication Possession Ratio>= 80%) among Selected Patient 
Characteristics 
 
 Beta OR 95 CI% 
low 
95% CI 
High 
P value 
      
Age group 
18-49 ref     
50-64 0.3835 1.467 1.283 1.679 <0.0001 
65+ 0.6401 1.897 1.488 2.418 <0.0001 
      
Gender 
   Male ref     
   Female -0.0959 0.909 0.802 1.030 0.1329 
      
Insulin 
No ref     
Yes -0.1323 0.876 0.771 0.995 0.0421 
      
Total Medication Counts 
1-7 Ref     
8-13 0.4011 1.493 1.279 1.744 <0.0001 
14-17 0.7855 2.194 1.810 2.659 <0.0001 
18+ 1.2471 3.480 2.905 4.170 <0.0001 
      
Comorbidity (Respiratory diseases) 
   No ref     
   Yes -0.1919 0.825 0.678 1.004 0.0552 
      
Comorbidity (Mental health disorders)  
   No ref     
   Yes -0.3248 0.723 0.611 0.855 0.0002 
      
Comorbidity (Cardiovascular diseases) 
   No ref     
   Yes -0.0946 0.910 0.748 1.106 0.3435 
      
Intervention 
No ref     
Yes -0.00516 0.995 0.755 1.312 0.9708 
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Table5: Fitted Logistic Regression Model with Adjusted Odds Ratio for 
Intervention versus Non-Intervention Status as a Predictor of Medication 
Adherence (MPR >= 80%), Controlling for Patient Age, Insulin Use, Number 
of Rx Utilized, and Presence of a Mental Health Disorder 
 
 Beta OR 95 CI% 
low 
95% CI 
High 
P value 
      
Age group 
18-49 Ref     
50-64 0.3772 1.458 1.276 1.667 <0.0001 
65+ 0.6211 1.861 1.464 2.365 <0.0001 
      
Insulin 
No Ref     
Yes -0.1350 0.874 0.769 0.993 0.0379 
      
Total Medication Counts 
1-7 Ref     
8-13 0.4004 1.492 1.279 1.742 <0.0001 
14-17 0.7705 2.161 1.784 2.618 <0.0001 
18+ 1.2102 3.354 2.809 4.005 <0.0001 
      
Comorbidity (Mental health disorders) 
   No Ref     
   Yes -0.3526 0.703 0.595 0.831 <0.0001 
      
Intervention 
No Ref     
Yes 0.00808 1.008 0.765 1.328 0.9542 
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Table6: Mean Annual Pharmacy, Medical, and Total Health Care Cost 
among Patients Participating in the Diabetes Incentive Program and Patients 
in the Comparison Group (Intervention vs. Nonintervention; N=5,812) 
 
 INTERVENTION NON-INTERVENTION  
 Mean ($) Sd Mean ($) Sd P value 
      
Pharmacy 2,904.92 2,890.37 2,655.21 3,265.73 0.2065 
PMPM 242.08  221.27   
      
Medical 5,922.08 13,303.75 7,438.93 16,889.93 0.1363 
PMPM 493.51  619.91   
      
Total 8,827.01 14,246.70 10,096.53 17,628.76 0.2327 
PMPM 735.58  841.38   
      
*PMPM = Per Member Per Month 
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Table 7: Mean Total Yearly Cost for Selected Characteristics of Patients 
Participating in the Diabetes Incentive Program and Patients in the 
Comparison Group (Intervention vs. Nonintervention). 
 
 INTERVENTION NON-INTERVENTION  
 Mean ($) Sd Mean ($) Sd P value 
Age group      
   0 (18-49) 7,015.2 8,664.0 8,244.1 13,869.2 0.4507 
   1 (50-64) 9,117.0 16,310.2 10,551.7 18,436.3 0.3112 
   2 (65+) 11,269.4 12,242.1 12,028.0 20,517.6 0.8314 
      
Gender      
   Male 7,761.1 10,070.4 9,785.9 18,450.7 0.1510 
   Female 10,513.0 19,008.7 10,583.1 16,250.3 0.9651 
Insulin      
No 7,521.2 11,343.2 8,818.1 15,866.6 0.2911 
Yes 10,803.1 17,635.6 12,422.3 20,247.1 0.4055 
Rx number      
1-7 4,495.2 4,717.4 6,261.6 12,887.4 0.2504 
8-13 6,836.4 7,214.9 7,661.0 13,806.1 0.5867 
14-17 7,689.9 9,152.6 9,380.5 14,393.5 0.4209 
18+ 15,362.3 23,032.0 15,548.9 23,261.4 0.9437 
Comorbidity (Respiratory diseases)  
   No 7,727.7 9,563.4 9,138.5 15,834.6 0.1518 
   Yes 23,337.4 38,971.4 17,937.7 27,097.8 0.3887 
      
Comorbidity (Mental health disorders) 
   No 8,302.2 14,837.1 8,827.1 15,617.6 0.6106 
   Yes 11,689.8 10,115.7 17,674.5 25,369.5 0.1198 
      
Comorbidity (Cardiovascular diseases) 
   No 7630.0 9920.0 8669.6 15239.4 0.2733 
   Yes 24627.6 37125.5 19503.9 26972.4 0.4076 
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Figure 1: Population Selection Flowchart 
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Appendix A: Metformin-Containing Combination Medications 
 
Actoplus met 
Avandamet 
Fortamet 
Glipizide/Metformin 
Glucophage 
Glucophage XR 
Glumetza 
Glyburide/Metformin 
Metaglip 
Metformin 
Metformin ER 
Riomet 
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Appendix B: ICD-9 Codes to Identify Respiratory Disease 
 
491.0 491.1 491.20 491.21 491.22 491.8 491.9 492.0 492.8 493.00 493.01 493.02 
493.10 493.11 493.12 493.20 493.21 493.22 493.81 493.82 493.90 493.91 493.92 
496 518.1 518.2 
 
Appendix C: Descriptions of Used ICD-9 Codes to Identify Respiratory 
Disease 
 
Code Description 
491 Chronic bronchitis 
492 Emphysema 
493 Asthma 
496 Chronic airway obstruction 
518 Other diseases of lung 
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Appendix D: ICD-9 Codes to Identify Mental Health Disorder 
 
295.00295.01295.02295.03295.04295.05295.10295.11295.12295.13295.14295152
95.20295.21 295.22295.23295.24295.25295.30295.31 
295.32295.33295.34295.35295.40295.41295.42295.43295.44295.45295.50295.51
295.52295.53295.54 
295.55295.60295.61295.62295.63295.64295.65295.70295.71295.72295.73295.74
295.75295.80295.81295.82295.83295.84295.85295.90295.91295.92295.93295.94
295.95296.00296.01296.02296.03296.04296.05296.06296.10296.11296.12296.13
296.14296.15296.16296.20296.21296.22296.23296.24296.25296.26296.30296.31
296.32296.33296.34296.35296.36296.40296.41296.42296.43296.44296.45296.46
296.50296.51296.52296.53296.54296.55296.56296.60296.61296.62296.63296.64
296.65296.66296.7296.80296.81296.82296.89296.90296.99297.0297.1297.2297.3
297.8297.9298.0298.1298.2298.3298.4298.8298.9299.00299.01299.10299.11299.
80299.81299.90299.91300.3300.4301.0301.10301.11301.12301.13301.20301.213
01.22301.23301.3301.4301.50301.51301.59301.6301.7301.80301.81301.82301.83
301.84301.89301.9308.0308.1308.2308.3308.4308.9309.0309.1309.21309.22309.
23309.24309.28309.29309.3309.4309.81309.82309.83309.89309.9311312.00312.
01312.02312.03312.10312.11312.12312.13312.20312.21312.22312.23312.30312.
31312.32312.33312.34312.35312.39312.4312.81312.82312.89312.9313.0313.131
3.21313.22313.23313.3313.81313.82313.83313.89313.9314.00314.01314.1314.23
14.8314.9 
 
Appendix E: Descriptions of Used ICD-9 Codes to Identify Mental Health 
Disorder 
 
Code Description 
295 Schizophrenia 
296 Episodic mood disorders including manic disorder, depression, 
and bipolar disorder 
297 Paranoia 
298 Other nonorganic psychoses 
299 Other psychoses specific to childhood 
300 Neurotic disorder 
301 Personality disorders 
308 Acute reaction of stress 
309 Adjustment reaction 
311 Depressive disorder 
312 Disturbance of conduct (specifically to childhood) 
313 Disturbance of emotions (specifically to childhood) 
314 Hyperkinetic syndrome (specifically to childhood) 
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Appendix F: ICD-9 Codes to Identify Cardiovascular Disease 
 
410.00410.01410.02410.10410.11410.12410.20410.21410.22410.30410.31410.32
410.40410.41410.42410.50410.51410.52410.60410.61410.62410.70410.71410.72
410.80410.81410.82410.90410.91410.92411.00411.10411.81411.89412.00413.00
413.10413.90414.00414.01414.02414.03414.04414.05414.06414.07414.10414.11
414.12414.19414.80414.90 
 
Appendix G: Descriptions of Used ICD-9 Codes to Identify Cardiovascular 
Disease 
 
Code Description 
410 Acute myocardial infarction 
412 Old myocardial infarction 
413 Angina 
414 Other forms of chronic ischemic heart disease 
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